NetworkNews Audio Announces Audio Press Release (APR) Discussing Overcoming Limitations on First-Generation GLP-1 Drug Therapies

59 minutes ago 3

Article content

AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) — via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “The Next Generation of the GLP-1 Revolution Is Already Underway,” featuring SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF).

Financial Post

THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY

Subscribe now to read the latest news in your city and across Canada.

  • Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
  • Daily content from Financial Times, the world's leading global business publication.
  • Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
  • National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
  • Daily puzzles, including the New York Times Crossword.

SUBSCRIBE TO UNLOCK MORE ARTICLES

Subscribe now to read the latest news in your city and across Canada.

  • Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
  • Daily content from Financial Times, the world's leading global business publication.
  • Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
  • National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
  • Daily puzzles, including the New York Times Crossword.

REGISTER / SIGN IN TO UNLOCK MORE ARTICLES

Create an account or sign in to continue with your reading experience.

  • Access articles from across Canada with one account.
  • Share your thoughts and join the conversation in the comments.
  • Enjoy additional articles per month.
  • Get email updates from your favourite authors.

THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.

Create an account or sign in to continue with your reading experience.

  • Access articles from across Canada with one account
  • Share your thoughts and join the conversation in the comments
  • Enjoy additional articles per month
  • Get email updates from your favourite authors

Sign In or Create an Account

or

Article content

To hear the NetworkNewsAudio version, visit: https://nnw.fm/OUoNE 

Article content

Article content

To read the original editorial, visit: https://nnw.fm/MTfXm

Article content

SureNano Science is advancing GEP-44 as a patented, next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs, positioning this emerging microcap as a minnow among giants quickly transitioning through the FDA pathway. Unlike conventional GLP-1 agonists that primarily target a single receptor pathway, GEP-44 functions as a triple agonist targeting GLP-1 and peptide YY receptors Y1 and Y2. This integrated mechanism is designed to simultaneously regulate glucose metabolism, suppress appetite and improve tolerability within a single molecule.

Article content

Article content

The compound was developed at Syracuse University and has demonstrated encouraging preclinical results. According to the company, GEP-44 produced meaningful reductions in food intake and body weight while also improving glycemic control in preclinical studies. Importantly, the compound reportedly avoided the nausea and gastrointestinal side effects commonly associated with many first-generation GLP-1 therapies, a factor that could become increasingly important as patient adoption expands.

Article content

By signing up you consent to receive the above newsletter from Postmedia Network Inc.

Article content

About SureNano Science Ltd.

Article content

SureNano Science Ltd. (CSE: SURE) is a Canadian life sciences company focused on acquiring, developing and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing global health markets. SureNano Science Ltd. has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential noninjectable delivery. The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano(TM) surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity, and taste. The Company has an exclusive license to distribute the SureNano(TM) surfactant within Canada; Oklahoma, USA; and Colorado, USA. SureNano Science Ltd. is now developing into a pharmaceutical focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease.

Article content

Article content

For more information, visit the company’s website at www.SureNano.com.

Article content

NOTE TO INVESTORS: The latest news and updates relating to SURNF are available in the company’s newsroom at https://ibn.fm/SURNF   

Article content

About NetworkNewsAudio

Article content

NetworkNewsAudio, a service of NetworkNewsWire (NNW), a multifaceted financial news and publishing company powered by IBN (“InvestorBrandNetwork”), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

Article content

For more information, visit: www.NetworkNewsAudio.com

Article content

NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today’s markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

Read Entire Article